Similar articles

• Phase II evaluation of amifostine as an esophageal mucosal protectant in the treatment of limited-stage small cell lung cancer with chemotherapy and twice-daily radiation.

  Arquette M, Wasserman T, Govindan R, Garfield D, Senzer N, Gillenwater H, Socinski M. Arquette M, et al. Semin Radiat Oncol. 2002 Jan;12(1 Suppl 1):59-61. doi: 10.1053/srao.2002.31375. Semin Radiat Oncol. 2002. PMID: 11917286 Clinical Trial.
• Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial.

  Komaki R, Lee JS, Milas L, Lee HK, Fossella FV, Herbst RS, Allen PK, Liao Z, Stevens CW, Lu C, Zinner RG, Papadimitrakopoulou VA, Kies MS, Blumenschein GR Jr, Pisters KM, Glisson BS, Kurie J, Kaplan B, Garza VP, Mooring D, Tucker SL, Cox JD. Komaki R, et al. Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1369-77. doi: 10.1016/j.ijrobp.2003.10.005. Int J Radiat Oncol Biol Phys. 2004. PMID: 15050312 Clinical Trial.
• A new administration schedule for amifostine as a radioprotector in cancer therapy.

  Wagner W, Radmard A, Schönekaes KG. Wagner W, et al. Anticancer Res. 1999 May-Jun;19(3B):2281-3. Anticancer Res. 1999. PMID: 10472344 Clinical Trial.
• Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: a meta-analysis.

  Mell LK, Malik R, Komaki R, Movsas B, Swann RS, Langer C, Antonadou D, Koukourakis M, Mundt AJ. Mell LK, et al. Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):111-8. doi: 10.1016/j.ijrobp.2006.11.043. Epub 2007 Feb 7. Int J Radiat Oncol Biol Phys. 2007. PMID: 17289291 Review.
• Pharmacologic normal tissue protection in clinical radiation oncology: focus on amifostine.

  Mell LK, Movsas B. Mell LK, et al. Expert Opin Drug Metab Toxicol. 2008 Oct;4(10):1341-50. doi: 10.1517/17425255.4.10.1341. Expert Opin Drug Metab Toxicol. 2008. PMID: 18798703 Review.